Paradoxical network excitation by glutamate release from VGluT3+ GABAergic interneurons

  1. Kenneth A Pelkey  Is a corresponding author
  2. Daniela Calvigioni
  3. Calvin Fang
  4. Geoffrey Vargish
  5. Tyler Ekins
  6. Kurt Auville
  7. Jason C Wester
  8. Mandy Lai
  9. Connie Mackenzie-Gray Scott
  10. Xiaoqing Yuan
  11. Steven Hunt
  12. Daniel Abebe
  13. Qing Xu
  14. Jordane Dimidschstein
  15. Gordon Fishell
  16. Ramesh Chittajallu
  17. Chris J McBain  Is a corresponding author
  1. NICHD/NIH, United States
  2. New York University Abu Dhabi, United Arab Emirates
  3. Broad Institute of MIT and Harvard, United States
  4. Harvard Medical School, United States

Abstract

In violation of Dale's principle several neuronal subtypes utilize more than one classical neurotransmitter. Molecular identification of vesicular glutamate transporter 3 and cholecystokinin expressing cortical interneurons (CCK+VGluT3+INTs) has prompted speculation of GABA/glutamate corelease from these cells for almost two decades despite a lack of direct evidence. We unequivocally demonstrate CCK+VGluT3+INT mediated GABA/glutamate cotransmission onto principal cells in adult mice using paired recording and optogenetic approaches. Although under normal conditions, GABAergic inhibition dominates CCK+VGluT3+INT signaling, glutamatergic signaling becomes predominant when glutamate decarboxylase (GAD) function is compromised. CCK+VGluT3+INTs exhibit surprising anatomical diversity comprising subsets of all known dendrite targeting CCK+ interneurons in addition to the expected basket cells, and their extensive circuit innervation profoundly dampens circuit excitability under normal conditions. However, in contexts where the glutamatergic phenotype of CCK+VGluT3+INTs is amplified, they promote paradoxical network hyperexcitability which may be relevant to disorders involving GAD dysfunction such as schizophrenia or vitamin B6 deficiency.

Data availability

All data analyzed in this study are included in the manuscript/supporting files.

Article and author information

Author details

  1. Kenneth A Pelkey

    Section on Cellular and Synaptic Physiology, NICHD/NIH, Bethesda, United States
    For correspondence
    pelkeyk2@mail.nih.gov
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-9731-1336
  2. Daniela Calvigioni

    Section on Cellular and Synaptic Physiology, NICHD/NIH, Bethesda, United States
    Competing interests
    The authors declare that no competing interests exist.
  3. Calvin Fang

    Section on Cellular and Synaptic Physiology, NICHD/NIH, Bethesda, United States
    Competing interests
    The authors declare that no competing interests exist.
  4. Geoffrey Vargish

    Section on Cellular and Synaptic Physiology, NICHD/NIH, Bethesda, United States
    Competing interests
    The authors declare that no competing interests exist.
  5. Tyler Ekins

    Section on Cellular and Synaptic Physiology, NICHD/NIH, Bethesda, United States
    Competing interests
    The authors declare that no competing interests exist.
  6. Kurt Auville

    Section on Cellular and Synaptic Physiology, NICHD/NIH, Bethesda, United States
    Competing interests
    The authors declare that no competing interests exist.
  7. Jason C Wester

    Section on Cellular and Synaptic Physiology, NICHD/NIH, Bethesda, United States
    Competing interests
    The authors declare that no competing interests exist.
  8. Mandy Lai

    Section on Cellular and Synaptic Physiology, NICHD/NIH, Bethesda, United States
    Competing interests
    The authors declare that no competing interests exist.
  9. Connie Mackenzie-Gray Scott

    Section on Cellular and Synaptic Physiology, NICHD/NIH, Bethesda, United States
    Competing interests
    The authors declare that no competing interests exist.
  10. Xiaoqing Yuan

    Section on Cellular and Synaptic Physiology, NICHD/NIH, Bethesda, United States
    Competing interests
    The authors declare that no competing interests exist.
  11. Steven Hunt

    Section on Cellular and Synaptic Physiology, NICHD/NIH, Bethesda, United States
    Competing interests
    The authors declare that no competing interests exist.
  12. Daniel Abebe

    Section on Cellular and Synaptic Physiology, NICHD/NIH, Bethesda, United States
    Competing interests
    The authors declare that no competing interests exist.
  13. Qing Xu

    Center for Genomics and Systems Biology, New York University Abu Dhabi, Abu Dhabi, United Arab Emirates
    Competing interests
    The authors declare that no competing interests exist.
  14. Jordane Dimidschstein

    Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, United States
    Competing interests
    The authors declare that no competing interests exist.
  15. Gordon Fishell

    Department of Neurobiology, Harvard Medical School, Boston, United States
    Competing interests
    The authors declare that no competing interests exist.
  16. Ramesh Chittajallu

    Section on Cellular and Synaptic Physiology, NICHD/NIH, Bethesda, United States
    Competing interests
    The authors declare that no competing interests exist.
  17. Chris J McBain

    Section on Cellular and Synaptic Physiology, NICHD/NIH, Bethesda, United States
    For correspondence
    mcbainc@mail.nih.gov
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-5909-0157

Funding

Eunice Kennedy Shriver National Institute of Child Health and Human Development (Intramural research program)

  • Chris J McBain

National Institute of Neurological Disorders and Stroke (NS081297; NS074972)

  • Gordon Fishell

National Institute of Mental Health (MH071679)

  • Gordon Fishell

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Ethics

Animal experimentation: All experiments were conducted in accordance with animal protocols approved by the National Institutes of Health (ASP# 17-045).

Copyright

This is an open-access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication.

Metrics

  • 3,993
    views
  • 635
    downloads
  • 37
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Kenneth A Pelkey
  2. Daniela Calvigioni
  3. Calvin Fang
  4. Geoffrey Vargish
  5. Tyler Ekins
  6. Kurt Auville
  7. Jason C Wester
  8. Mandy Lai
  9. Connie Mackenzie-Gray Scott
  10. Xiaoqing Yuan
  11. Steven Hunt
  12. Daniel Abebe
  13. Qing Xu
  14. Jordane Dimidschstein
  15. Gordon Fishell
  16. Ramesh Chittajallu
  17. Chris J McBain
(2020)
Paradoxical network excitation by glutamate release from VGluT3+ GABAergic interneurons
eLife 9:e51996.
https://doi.org/10.7554/eLife.51996

Share this article

https://doi.org/10.7554/eLife.51996

Further reading

    1. Medicine
    2. Neuroscience
    Ayni Sharif, Matthew S Jeffers ... Manoj M Lalu
    Research Article

    C-C chemokine receptor type 5 (CCR5) antagonists may improve both acute stroke outcome and long-term recovery. Despite their evaluation in ongoing clinical trials, gaps remain in the evidence supporting their use. With a panel of patients with lived experiences of stroke, we performed a systematic review of animal models of stroke that administered a CCR5 antagonist and assessed infarct size or behavioural outcomes. MEDLINE, Web of Science, and Embase were searched. Article screening and data extraction were completed in duplicate. We pooled outcomes using random effects meta-analyses. We assessed risk of bias using the Systematic Review Centre for Laboratory Animal Experimentation (SYRCLE) tool and alignment with the Stroke Treatment Academic Industry Roundtable (STAIR) and Stroke Recovery and Rehabilitation Roundtable (SRRR) recommendations. Five studies representing 10 experiments were included. CCR5 antagonists reduced infarct volume (standard mean difference −1.02; 95% confidence interval −1.58 to −0.46) when compared to stroke-only controls. Varied timing of CCR5 administration (pre- or post-stroke induction) produced similar benefit. CCR5 antagonists significantly improved 11 of 16 behavioural outcomes reported. High risk of bias was present in all studies and critical knowledge gaps in the preclinical evidence were identified using STAIR/SRRR. CCR5 antagonists demonstrate promise; however, rigorously designed preclinical studies that better align with STAIR/SRRR recommendations and downstream clinical trials are warranted. Prospective Register of Systematic Reviews (PROSPERO CRD42023393438).

    1. Neuroscience
    Yisi Liu, Pu Wang ... Hongwei Zhou
    Short Report

    The increasing use of tissue clearing techniques underscores the urgent need for cost-effective and simplified deep imaging methods. While traditional inverted confocal microscopes excel in high-resolution imaging of tissue sections and cultured cells, they face limitations in deep imaging of cleared tissues due to refractive index mismatches between the immersion media of objectives and sample container. To overcome these challenges, the RIM-Deep was developed to significantly improve deep imaging capabilities without compromising the normal function of the confocal microscope. This system facilitates deep immunofluorescence imaging of the prefrontal cortex in cleared macaque tissue, extending imaging depth from 2 mm to 5 mm. Applied to an intact and cleared Thy1-EGFP mouse brain, the system allowed for clear axonal visualization at high imaging depth. Moreover, this advancement enables large-scale, deep 3D imaging of intact tissues. In principle, this concept can be extended to any imaging modality, including existing inverted wide-field, confocal, and two-photon microscopy. This would significantly upgrade traditional laboratory configurations and facilitate the study of connectomes in the brain and other tissues.